Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Subcutaneous epcoritamab appears to be effective following complete response among patients with relapsed/refractory large B-cell lymphoma (LBCL), according to research presented at the ASCO Annual Meeting 2023.
Data from the phase 1/2 EPCORE NHL-1 study (ClinicalTrials.gov Identifier: NCT03625037) showed that epcoritamab is safe and clinical active in this patient population. Researchers presented updated results from EPCORE NHL-1 highlighting longer-term follow-up analyses.
By November 2022, 157 patients had been enrolled, including 139 patients with diffuse large B-cell lymphoma. In the overall cohort, the median age was 64 years, 70% of patients had received at least 3 prior therapy lines, and 39% of patients had received prior chimeric antigen receptor (CAR) T-cell therapy.
The median follow-up was 20 months. After this point, analysis showed that the overall response rate was 63% (95% CI, 55-71); the complete response rate was 39% (95% CI, 32-48). The median times to response and complete response were, furthermore, 1.4 and 2.7 months, respectively.
The median duration of response was 15.5 months and not reached among patients who had received prior CAR-T therapy. Among complete responders, median progression-free survival and median overall survival were not reached.
A total of 51% of patients had any-grade cytokine release syndrome; 24% of patients developed neutropenia, 24% of patients developed pyrexia, and 23% of patients had fatigue. Fatal treatment-related events were observed in 15 patients.
“These data support the ongoing phase 3 studies evaluating epcoritamab across different lines of treatment and in various combinations for LBCL,” Yasmin Karimi, MD, of the University of Michigan Comprehensive Cancer Center in Ann Arbor, MI, noted in her presentation.
Disclosures: This research was supported by Genmab A/S and AbbVie. Please see the original reference for a full list of disclosures.
Reference
Karimi Y, Ghesquieres H, Jurczak W, et al. Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial. SCO 2023. June 2-6, 2023. Abstract 7525.
This article originally appeared on Hematology Advisor
